Treatment satisfaction and patient preference for efanesoctocog alfa over previous hemophilia A treatment: Results from the XTEND-1 phase 3 clinical trial

This publication has 18 references indexed in Scilit:

• Patient Experience With Efanesoctocog Alfa for Severe Hemophilia A: Results From the XTEND-1 Phase 3 Clinical Study Exit Interviews
  Clinical Therapeutics, 2024
• Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A
  New England Journal of Medicine, 2024
• Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind
  Journal of Thrombosis and Haemostasis, 2024
• Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A
  Blood Reviews, 2023
• Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A
  New England Journal of Medicine, 2023
• Treatment satisfaction and limitations in haemophilia A, with a focus on factor VIII product storage conditions: patients’ perspectives and challenges
  Drugs & Therapy Perspectives, 2022
• The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
  Research and Practice in Thrombosis and Haemostasis, 2021
• Nonfactor Therapies: New Approaches to Prophylactic Treatment of Haemophilia
  Hamostaseologie, 2021
• Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)
  The Patient - Patient-Centered Outcomes Research, 2019
• The past and future of haemophilia: diagnosis, treatments, and its complications
  The Lancet, 2016